Anticoagulation after ischemic stroke: start, restart, or replace — when and what?

Abstract

Stroke is the leading cause of acquired disability in adults worldwide, and preventing the recurrence of stroke is a long-standing question in the field of neurology. For cardiogenic stroke, anticoagulation therapy is the most important method of preventing recurrence. We aimed to investigate the similarities and differences between the international guidelines as for the anticoagulation therapy of cardiogenic stroke. These included the America, Canadian, British/Irish and European guidelines. We classified the guidelines by the cardiogenic event and if there was previous therapy.